These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38740087)

  • 1. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
    Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
    Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
    Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
    J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD.
    McLeod M; Chang MC; Rushin A; Ragavan M; Mahar R; Sharma G; Badar A; Giacalone A; Glanz ME; Malut VR; Graham D; Sunny NE; Bankson JA; Cusi K; Merritt ME
    Cell Rep Med; 2024 Sep; 5(9):101714. PubMed ID: 39241774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.
    Rajas F; Dentin R; Cannella Miliano A; Silva M; Raffin M; Levavasseur F; Gautier-Stein A; Postic C; Mithieux G
    Mol Metab; 2021 Jan; 43():101108. PubMed ID: 33137488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice.
    Wang H; Dolezal JM; Kulkarni S; Lu J; Mandel J; Jackson LE; Alencastro F; Duncan AW; Prochownik EV
    J Biol Chem; 2018 Sep; 293(38):14740-14757. PubMed ID: 30087120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krüppel-like factor 10 protects against metabolic dysfunction-associated steatohepatitis by regulating HNF4α-mediated metabolic pathways.
    Pan X; Hu S; Xu Y; Gopoju R; Zhu Y; Cassim Bawa FN; Wang H; Wang J; Batayneh Z; Clark A; Zeng Y; Lin L; Wang X; Yin L; Zhang Y
    Metabolism; 2024 Jun; 155():155909. PubMed ID: 38582490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hepatic BMAL1/AKT/lipogenesis axis protects against alcoholic liver disease in mice via promoting PPARα pathway.
    Zhang D; Tong X; Nelson BB; Jin E; Sit J; Charney N; Yang M; Omary MB; Yin L
    Hepatology; 2018 Sep; 68(3):883-896. PubMed ID: 29534306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.
    Zhang S; Guo F; Yu M; Yang X; Yao Z; Li Q; Wei Z; Feng K; Zeng P; Zhao D; Li X; Zhu Y; Miao QR; Iwakiri Y; Chen Y; Han J; Duan Y
    J Hepatol; 2020 Dec; 73(6):1482-1495. PubMed ID: 32738448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression.
    Dentin R; Pégorier JP; Benhamed F; Foufelle F; Ferré P; Fauveau V; Magnuson MA; Girard J; Postic C
    J Biol Chem; 2004 May; 279(19):20314-26. PubMed ID: 14985368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish.
    Gong Y; Lu Q; Xi L; Liu Y; Yang B; Su J; Liu H; Jin J; Zhang Z; Yang Y; Zhu X; Xie S; Han D
    J Nutr Biochem; 2023 Dec; 122():109452. PubMed ID: 37748621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
    Fisher FM; Kim M; Doridot L; Cunniff JC; Parker TS; Levine DM; Hellerstein MK; Hudgins LC; Maratos-Flier E; Herman MA
    Mol Metab; 2017 Jan; 6(1):14-21. PubMed ID: 28123933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice.
    Jois T; Chen W; Howard V; Harvey R; Youngs K; Thalmann C; Saha P; Chan L; Cowley MA; Sleeman MW
    Mol Metab; 2017 Nov; 6(11):1381-1394. PubMed ID: 29107286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1.
    Zhu C; Huang M; Kim HG; Chowdhury K; Gao J; Liu S; Wan J; Wei L; Dong XC
    Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166249. PubMed ID: 34425214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
    Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
    Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.